QGENHealthcare · Diagnostics & ResearchThe 12 Wall Street analysts covering QIAGEN NV hold a median 12-month price target of $52 — +3.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores QIAGEN NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Issuance (40): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Oct 2026 | Barclays | Downgrade | Equal-Weight | $55 → $53 |
| 26 Oct 2026 | Citigroup | Maintains | Neutral | $45 → $52 |
| 22 Oct 2026 | Baird | Maintains | Outperform | $50 → $52 |
| 22 Oct 2026 | JP Morgan | Downgrade | Neutral | $55 → $52 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | — |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $50 → $55 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | $40 → $55 |
| 6 Oct 2026 | Barclays | Upgrade | Overweight | — |
| 9 Sept 2026 | UBS | Maintains | Neutral | — |
| 9 Sept 2026 | UBS | Maintains | Neutral | $52 → $47 |
| 10 Aug 2026 | Citigroup | Maintains | Neutral | $38 → $45 |
| 10 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 7 Aug 2026 | Barclays | Maintains | Equal-Weight | $38 → $40 |
| 7 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $45 → $50 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 23 June 2026 | Morgan Stanley | Upgrade | Overweight | $40 → $42 |
| 23 June 2026 | Morgan Stanley | Upgrade | Overweight | — |
| 18 May 2026 | Stifel | Maintains | Hold | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
QGEN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, QIAGEN NV returned +7.6% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 24% of US stocks
Cheaper than 30% of US stocks
Cheaper than 23% of US stocks
Higher than 28% of US stocks
Higher than 45% of US stocks
Higher than 77% of US stocks
Higher than 85% of US stocks
Higher than 82% of US stocks
Higher than 68% of US stocks
Higher than 81% of US stocks
Higher than 67% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
QIAGEN NV has a market value of $10.4B and an enterprise value of $11.2B.
Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 0.3% year on year.
Net income over the same four quarters: $409.3M, a 19.5% net margin.
Diluted earnings per share, trailing twelve months: $1.98.
Free cash flow in the twelve months to 30 June 2026: $440.6M.
Trailing P/E: 25.5×; forward P/E: 19.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.70%, paying out 18% of earnings.
QIAGEN NV employs 5,500 people — $382K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own QIAGEN NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Qiagen has what it describes as the two key ingredients for a likely earnings beat in its upcoming Q3 report. The article previews expectations ahead of the release.
Why it matters — QGEN watchers may find the preview relevant as they follow expectations for the company’s Q3 earnings report.
Brodsky & Smith said it is investigating QIAGEN N.V. among several companies and invited shareholders to contact the firm to discuss the investigation.
Why it matters — QGEN shareholders may wish to note the announced investigation and the firm’s invitation to discuss it.
Brodsky & Smith announced an investigation involving QIAGEN N.V. and three other companies, and invited shareholders to contact the firm to discuss it.
Why it matters — The notice concerns QIAGEN shareholders, but the excerpt does not describe the investigation’s subject or any findings.
The headline says an analyst covering Qiagen is no longer bullish and lists the item among Thursday’s top three downgrades. The excerpt provides no analyst name, rating details, or rationale.
Why it matters — A change to a less bullish analyst outlook may be relevant to QGEN watchers, though the excerpt does not specify the details.
Halper Sadeh LLC is investigating whether QIAGEN and its board violated federal securities laws in connection with the proposed sale to the EQT XI fund for €46.50 in cash per share. The firm is inviting QIAGEN shareholders to contact it about their rights and options.
Why it matters — The investigation concerns the proposed sale terms and the conduct of QIAGEN’s board, matters relevant to shareholders following the transaction.
The 12 Wall Street analysts covering QIAGEN NV have a median 12-month price target of $52, with estimates ranging from $40 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering QIAGEN NV, 2 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks QIAGEN NV 76 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, QIAGEN NV ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +3.3% from the last close, and Ticker Nerd's factor model ranks QIAGEN NV 76 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering QIAGEN NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $55 over the next 12 months.
QIAGEN NV returned +7.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research.
The most recent item we track (Zacks Investment Research, 28 Oct 2026): "Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release". Zacks Investment Research says Qiagen has what it describes as the two key ingredients for a likely earnings beat in its upcoming Q3 report. The article previews expectations ahead of the release.
Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.
CEO Mr. Jonathan M. Pratt · 5,500 employees · Netherlands · https://www.qiagen.com
